Innovent Biologics

Innovent Biologics To empower patients worldwide with affordable, high-quality biopharmaceuticals Innovent has launched 17 products in the market.

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. It has 1 new drug applications under regulatory review, 4 assets in Phase 3 or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Roche, Takeda, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action" Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Innovent has successfully dosed the first participant in the pivotal Phase 3 HeriCare-Breast01 study evaluating IBI354, ...
13/02/2026

Innovent has successfully dosed the first participant in the pivotal Phase 3 HeriCare-Breast01 study evaluating IBI354, a novel HER2 ADC, as a first-line treatment for unresectable locally advanced or metastatic HER2-positive breast cancer.

With two global Phase 3 trials underway, IBI354 represents a next-generation antibody–drug conjugate designed for high potency and low toxicity, aiming to further advance the standard of care. We’re encouraged to see this study move forward and hopeful it will help bring another meaningful option to patients facing HER2-positive disease.https://www.prnewswire.com/news-releases/innovent-dosed-first-participant-in-phase-3-clinical-study-of-ibi354-novel-her2-adc-for-first-line-treatment-of-her2-positive-breast-cancer-302686402.html

Women are integral to Innovent's work. They drive progress from the earliest questions to the moment new therapies reach...
11/02/2026

Women are integral to Innovent's work. They drive progress from the earliest questions to the moment new therapies reach patients, making sense of complex data, guiding programs through development and approval, and helping turn science into real-world impact. Across R&D, clinical operations, manufacturing, quality, medical affairs, finance, and beyond, women bring together STEM expertise and social science perspectives to build better studies, stronger systems, and more equitable access to innovation. As this year's International Day of Women and Girls in Science calls attention to the power of combining AI, social science, STEM, and finance, we see that collaboration at work every day in gender-balanced teams and women leaders scaling impact with care and responsibility. Today and every day, we recognize their contributions and reaffirm our commitment to building inclusive, sustainable futures for women and girls in science.




Today, Innovent announced a strategic collaboration with Eli Lilly and Company to advance novel biologic medicines in on...
08/02/2026

Today, Innovent announced a strategic collaboration with Eli Lilly and Company to advance novel biologic medicines in oncology and immunology, marking the seventh collaboration between our two companies.

This agreement reflects an innovative model beyond traditional licensing, creating an end-to-end innovation ecosystem that brings together Innovent's agile discovery and early-stage development engine with Lilly's global development and commercialization capabilities.

Together, we are expanding what is possible in biologic innovation and working to translate scientific breakthroughs into meaningful advances for patients worldwide.

For more details, please see the full press release.https://www.prnewswire.com/news-releases/innovent-announces-strategic-collaboration-with-lilly-to-develop-new-medicines-globally-in-oncology-and-immunology-302682009.html

For , this year's United by Unique campaign underscores that while cancer affects millions, every patient's biology and...
04/02/2026

For , this year's United by Unique campaign underscores that while cancer affects millions, every patient's biology and experience are distinct and deserve to be addressed as such. At Innovent, we believe advancing patient-centered, evidence-based cancer care starts with translating rigorous science into precision medicines that target disease mechanisms while reflecting the heterogeneity of cancer and the people living with it. Through continued investment in oncology research, biomarker-driven development, and global collaboration, we remain committed to contributing to a future where cancer care is both scientifically precise and deeply human.

We're pleased to announce that Innovent's tri-specific antibody IBI3003 (GPRC5D/BCMA/CD3) has received Fast Track Design...
27/01/2026

We're pleased to announce that Innovent's tri-specific antibody IBI3003 (GPRC5D/BCMA/CD3) has received Fast Track Designation from the U.S. FDA for the treatment of relapsed or refractory multiple myeloma in patients who have received four or more prior lines of therapy. IBI3003, developed using Innovent’s proprietary Sanbody® platform, is in Phase 1/2 clinical trials in China and Australia, with a U.S. Phase 1/2 study planned imminently following encouraging safety and efficacy data presented at ASH 2025. The Fast Track Designation underscores the potential of IBI3003 to address significant unmet medical needs and supports closer FDA engagement to help accelerate its clinical development. https://www.prnewswire.com/news-releases/innovent-announces-ibi3003-gprc5dbcmacd3-trispecific-antibody-receives-fast-track-designation-from-the-us-fda-for-relapsed-or-refractory-multiple-myeloma-302669853.html

We're pleased to share that our partner Ollin Biosciences announced positive topline results from the randomized Phase 1...
14/01/2026

We're pleased to share that our partner Ollin Biosciences announced positive topline results from the randomized Phase 1b JADE study, demonstrating superior outcomes for IBI324, a next-generation VEGF/Ang2 bispecific antibody, versus faricimab (Vabysmo®) in diabetic macular edema and comparable outcomes in wet age-related macular degeneration. In DME, IBI324 delivered faster and greater retinal drying, with a substantially higher proportion of patients achieving absence of edema by Week 12, alongside rapid and sustained vision gains across both indications. We look forward to sharing more as the full data are presented at AED 2026 and as Ollin provides additional updates at the 2026 J.P. Morgan Healthcare Conference. https://en.prnasia.com/releases/global/innovent-s-partner-ollin-biosciences-announces-positive-topline-data-with-superior-outcomes-from-a-randomized-head-to-head-study-of-ibi324-compared-to-faricimab-vabysmo-in-diabetic-macular-edema-and-wet-age-related-macular-degeneration-518550.shtml

As we step into 2026, we express our gratitude to our partners, colleagues, and communities for their support. We celebr...
01/01/2026

As we step into 2026, we express our gratitude to our partners, colleagues, and communities for their support. We celebrate our shared progress and remain focused on driving meaningful innovation that improves patient lives and strengthens our global community.

31/12/2025

As Innovent enters its 14th year, we look back with gratitude on a year of steady and meaningful progress in 2025. Our commercial portfolio expanded to 18 approved therapies, reflecting continued momentum across both our oncology and general biomedicine pipelines. Over the past year, we introduced important new medicines, including an anti-CTLA-4 immunotherapy, a dual-target metabolic therapy for weight management and glucose control, a therapy for thyroid eye disease, and a next-generation IL-23p19 inhibitor addressing inflammatory conditions. Each of these therapies is designed to address significant unmet clinical needs and expand high-quality treatment options for patients. We also increased patient access through the addition of several innovative medicines to China’s National Reimbursement Drug List. With appreciation for our colleagues, partners, and community, we look ahead to 2026 with focus and purpose, and remain committed to advancing innovation that improves patient health globally.

Wishing a joyful new year to all!

Happy Holidays from our team! Thank you to our partners, colleagues, and community for your trust and support throughout...
25/12/2025

Happy Holidays from our team! Thank you to our partners, colleagues, and community for your trust and support throughout the year. We look forward to continuing our shared progress and collaboration in the year ahead.

We are thrilled to share that TABOSUN® (ipilimumab N01 injection), China's first domestic anti-CTLA-4 antibody, has rece...
25/12/2025

We are thrilled to share that TABOSUN® (ipilimumab N01 injection), China's first domestic anti-CTLA-4 antibody, has received NMPA approval in combination with TYVYT® for the neoadjuvant treatment of patients with stage IIB–III resectable MSI-H/dMMR colon cancer.

This dual-immunotherapy regimen demonstrated strong improvements in pathological complete response and enabled many patients to avoid additional postoperative chemotherapy. The approval addresses an important gap in early-stage treatment and expands meaningful options for patients and clinicians. As Innovent's 18th approved product, TABOSUN® reflects the continued growth of our immuno-oncology portfolio and underscores our long-term commitment to developing high-quality therapies that advance standards of care and benefit patients worldwide. https://www.prnewswire.com/news-releases/chinas-first-domestic-anti-ctla-4-monoclonal-antibody-innovents-tabosun-ipilimumab-n01-injection-received-nmpa-approval-302649444.html

We're excited to share that our latest research has been published in Nature. The DREAMS-1 and DREAMS-2 Phase 3 studies ...
18/12/2025

We're excited to share that our latest research has been published in Nature. The DREAMS-1 and DREAMS-2 Phase 3 studies of mazdutide in Chinese adults with type 2 diabetes appeared back-to-back as Accelerated Article Previews, adding to the growing body of evidence supporting China-led innovation in metabolic disease research. https://www.prnewswire.com/news-releases/nature--two-phase-3-clinical-results-of-mazdutide-glp-1gcg-dual-receptor-agonist-in-chinese-adults-with-type-2-diabetes-have-been-back-to-back-published-in-nature-302644606.html

Address

Suzhou
215028

Telephone

+8651269566088

Website

Alerts

Be the first to know and let us send you an email when Innovent Biologics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Innovent Biologics:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category